Abstract
Alzheimers disease is a progressive brain disorder that gradually destroys a patients memory function and ability to carry out daily activities. According to the prevailing amyloid cascade hypothesis, Alzheimers disease is initiated by amyloid ß-peptide accumulation leading to neuronal toxicity. The neurofibrillary tangle deriving from hyperphosphorylated tau and synapse loss are also key features for Alzheimers disease. Recent studies revealed a significant comorbidity of Alzheimers disease and cerebrovascular disease suggesting that cerebrovascular dysregulation is an important feature of Alzheimers disease. This mini-review will discuss the hypothesis that a dysfunction of the vascular system may result in damage of the neurovascular unit, initiating a cascade of events. An overlap with other forms of cognitive impairment, such as mild cognitive impairment, or vascular dementia will be discussed.
Keywords: vascular system, alzheimer, vascular dementia, hypothesis, cascade
Current Neurovascular Research
Title: Cerebrovascular Damage as a Cause for Alzheimers Disease
Volume: 2 Issue: 4
Author(s): C. Humpel and J. Marksteiner
Affiliation:
Keywords: vascular system, alzheimer, vascular dementia, hypothesis, cascade
Abstract: Alzheimers disease is a progressive brain disorder that gradually destroys a patients memory function and ability to carry out daily activities. According to the prevailing amyloid cascade hypothesis, Alzheimers disease is initiated by amyloid ß-peptide accumulation leading to neuronal toxicity. The neurofibrillary tangle deriving from hyperphosphorylated tau and synapse loss are also key features for Alzheimers disease. Recent studies revealed a significant comorbidity of Alzheimers disease and cerebrovascular disease suggesting that cerebrovascular dysregulation is an important feature of Alzheimers disease. This mini-review will discuss the hypothesis that a dysfunction of the vascular system may result in damage of the neurovascular unit, initiating a cascade of events. An overlap with other forms of cognitive impairment, such as mild cognitive impairment, or vascular dementia will be discussed.
Export Options
About this article
Cite this article as:
Humpel C. and Marksteiner J., Cerebrovascular Damage as a Cause for Alzheimers Disease, Current Neurovascular Research 2005; 2 (4) . https://dx.doi.org/10.2174/156720205774322610
| DOI https://dx.doi.org/10.2174/156720205774322610 |
Print ISSN 1567-2026 |
| Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
Call for Papers in Thematic Issues
Network Pharmacology in Multi-Target Neurotherapeutics: A Systems Approach to Brain Disorders
Neurological disorders such as Alzheimer’s, Parkinson’s, and other neurodegenerative diseases are complex, multifactorial conditions involving intricate molecular networks that challenge traditional single-target therapeutic strategies. This thematic issue explores the paradigm of multi-target neurotherapeutics guided by network pharmacology, offering a holistic framework to decode disease complexity and identify synergistic therapeutic mechanisms. ...read more
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
HERVs Role in the Pathogenesis, Diagnosis or Prognosis of Aging
Diseases: A Systematic Review
Current Molecular Medicine Role of Protein Conformational Dynamics and DNA Integrity in Relevance to Neuronal Cell Death in Neurodegeneration
Current Alzheimer Research The Clinical Impact of Quantitative Cell-free DNA, KRAS, and BRAF Mutations on Response to Anti-EGFR Treatment in Patients with Metastatic Colorectal Cancer
Current Pharmaceutical Design Huntingtons Disease: New Frontiers for Molecular and Cell Therapy
Current Drug Targets Lipid Raft Alterations in Aged-Associated Neuropathologies
Current Alzheimer Research Anti-Inflammatory Agents from Plants: Progress and Potential
Current Medicinal Chemistry Oxidative Stress, Inflammation and Endothelial Biomarkers in Arterial Hypertension
Current Hypertension Reviews Revisiting Purine Nucleoside Cholinesterase Inhibitors - An Experimental Glycon Structure/Activity Relationship Study
Medicinal Chemistry Design of Some New Potent Beta-secretase Inhibitors Based on QSAR and Molecular Modeling Study on a Series of Hydroxyethylamine Derivatives
Letters in Drug Design & Discovery Current & Future Therapies of Erectile Dysfunction in Neurological Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Advances in Bioconjugation
Current Organic Chemistry Decoding Common Features of Neurodegenerative Disorders: From Differentially Expressed Genes to Pathways
Current Genomics Repurposing of Antidiarrheal Loperamide for Treating Melanoma by Inducing Cell Apoptosis and Cell Metastasis Suppression <i>In vitro</i> and <i>In vivo</i>
Current Cancer Drug Targets A Computational Approach to Finding RNA Tertiary Motifs in Genomic Sequences: A Case Study
Recent Patents on DNA & Gene Sequences Progress in Understanding Basal Ganglia Dysfunction as a Common Target for Methamphetamine Abuse and HIV-1 Neurodegeneration
Current HIV Research Metformin Eased Cognitive Impairment Induced by Chronic L-methionine Administration: Potential Role of Oxidative Stress
Current Neuropharmacology Transcriptomics Study of Neurodegenerative Disease: Emphasis on Synaptic Dysfunction Mechanism in Alzheimer's Disease
CNS & Neurological Disorders - Drug Targets Melatonin Receptor as a Drug Target for Neuroprotection
Current Molecular Pharmacology Visualising Neuroinflammation in Post-Stroke Patients: A Comparative PET Study with the TSPO Molecular Imaging Biomarkers [<sup>11</sup>C]PK11195 and [<sup>11</sup>C]vinpocetine
Current Radiopharmaceuticals Strategies of Engineering Nanoparticles for Treating Neurodegenerative Disorders
Current Drug Metabolism





